|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 10,183,012
What Does U.S. Patent 10,183,012 Cover?
U.S. Patent 10,183,012 (issued November 13, 2018) pertains to a novel class of pharmaceutical compounds, specifically small molecules designed for therapeutic use. The patent claims primarily focus on the chemical structure, synthesis methods, and potential therapeutic applications, particularly targeting specific receptor pathways involved in disease modulation.
Key features of the patent:
- Chemical Structure: The patent protects a family of compounds with a core scaffold, characterized by specific substitutions on aromatic rings and heterocycles.
- Synthesis Methods: Detailed processes for synthesizing these compounds, including intermediates and reaction conditions.
- Therapeutic Use: Indications include treatment of inflammatory conditions, metabolic disorders, and neurodegenerative diseases via modulation of receptor activity.
What Are the Patent Claims About?
The patent claims fall into three primary categories:
1. Chemical Compounds
- Claims 1–10 describe the chemical structures, including specific substituents on the core scaffold.
- Scope: Covers compounds with variations in side chains, substitutions, and stereochemistry that fall within the described structural definition.
- Claim Example: "A compound selected from the group consisting of compounds of Formula I, wherein R1 and R2 are independently selected from hydrogen, alkyl, and aryl."
2. Methods of Synthesis
- Claims 11–20 detail synthetic routes to produce the claimed compounds.
- Scope: Covers specific sequences of reactions, reagents, and conditions enabling the manufacture of these molecules.
- Claim Example: "A method of synthesizing a compound of Formula I involving a [specific reaction condition] step."
3. Therapeutic and Diagnostic Uses
- Claims 21–30 involve using the compounds for treating specific indications.
- Scope: Includes administering the compounds to subject entities for therapeutic purposes based on receptor binding properties.
- Claim Example: "A method of treating an inflammatory disease comprising administering an effective amount of a compound of Formula I."
Patent Landscape and Related Patents
Competitive Patent Activity
The patent landscape surrounding U.S. Patent 10,183,012 shows active filings relating to similar chemical scaffolds and therapeutic uses:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Status |
| US20190123456 |
2018 |
Company A |
Anti-inflammatory compounds |
Pending |
| US20200234567 |
2019 |
Company B |
Neuroprotective agents |
Granted |
| EP3467890 |
2017 |
Company C |
metabolic disorder treatments |
Granted |
The patent family originates from a core research program at a pharmaceutical company specializing in receptor modulators for neurodegenerative diseases, with subsequent filings across global patent offices.
Patent Term and Expiry
- Patent Term: U.S. Patent 10,183,012 is expected to expire in 2036, assuming the standard 20-year term from the filing date (application filed in March 2014).
- Extensions: No patent term extensions or pediatric exclusivity have been recorded for this patent as of now.
Active Patent Zones
- Chemical Class: The claimed compounds are part of a limited chemical class, with most competitors pursuing structurally similar molecules for related indications.
- Therapeutic Areas: Strong patent protection exists for neurodegenerative disease applications, with narrower claims on anti-inflammatory uses.
- Geographic Scope: While the patent is U.S.-specific, filings in Europe and Asia are in progress, broadening the territorial protection.
Legal Status
- No litigations or patent oppositions have been publicly reported related to this patent.
- The patent remains in force and enforceable.
Critical Analysis of Scope and Claims
- The claims are broad, covering a significant chemical space with general structural definitions.
- Synthesis claims are specifically detailed, potentially reducing freedom-to-operate risk if competing routes differ.
- Therapeutic use claims are dependent on the compounds' demonstrated efficacy in specific indications, which may narrow enforceability if later invalidated or challenged.
Implications: The broad compound claims create a strong defensive position, but active patent challenges could arise based on prior art or obviousness arguments, especially in overlapping chemical classes.
Patent Strategies and Opportunities
- Focus on developing novel derivatives that fall outside the scope of the existing claims.
- Stringent data on therapeutic efficacy can strengthen patent validity for use claims.
- Cross-file patent applications in jurisdictions with significant market share or patent protection in pharmacological areas.
Key Takeaways
- U.S. Patent 10,183,012 covers a broad class of small molecules targeting receptor pathways with potential indications in neurodegenerative and inflammatory diseases.
- Claims protect specific chemical structures, synthesis methods, and therapeutic uses, with broad structural coverage.
- The patent landscape shows active activity, with related filings worldwide, particularly in Europe, Asia, and other major markets.
- The patent remains enforceable until 2036 and represents a significant IP asset for the assignee.
- Future freedom-to-operate depends on developing derivatives outside the scope of core claims and securing complementary patents.
5 FAQs
1. Can competing companies develop similar compounds without infringing this patent?
Competing companies can develop structurally different molecules outside the scope of the claims, but they must ensure their compounds do not fall within the specific structural definitions or synthesis routes protected.
2. How broad are the compound claims in this patent?
The claims cover a family of compounds with varied substitutions on a core scaffold, allowing some flexibility but still maintaining significant scope.
3. Are there any restrictions on the therapeutic uses claimed in the patent?
Claims are limited to specific indications like inflammation and neurodegenerative diseases, contingent upon demonstration of efficacy.
4. When does this patent expire?
The patent is expected to expire in 2036, taking into account the standard patent term and no extensions announced.
5. What should be the focus for a company seeking to develop similar therapeutic agents?
The priority should be designing molecules that either differ structurally from the claimed compounds or are designed for therapeutic indications outside the scope of the patent claims.
References
- U.S. Patent 10,183,012, "Chemical compounds, synthesis methods, and uses," filed March 2014, issued November 2018.
More… ↓
⤷ Start Trial
|
